Skip to Content

Cariprazine Pregnancy and Breastfeeding Warnings

Cariprazine is also known as: Vraylar

Cariprazine Pregnancy Warnings

Advise pregnant women of the potential risk to the fetus. Comments: Neonates exposed to antipsychotic drugs during the third trimester of pregnancy should be monitored for extrapyramidal and/or withdrawal symptoms post-delivery. US FDA pregnancy category: Not assigned

Based on animal data, this drug may cause fetal harm. Pregnant rats receiving 0.2 to 3.5 times the maximum recommended human dose experienced fetal developmental toxicity (e.g. low body weight, skeletal malformations, or underdeveloped renal papillae). Impaired fertility was observed in female rats at all dose levels. There are no controlled data in human pregnancy. There have been reports of extrapyramidal and withdrawal symptoms in neonates exposed to antipsychotic drugs during the third trimester of pregnancy. These complications have varied in severity, from self-limited to needing intensive care unit support and prolonged hospitalization. Pregnancy registry: Physicians are encouraged to register patients and pregnant women are encouraged to register themselves by calling 1-866-961-2388 or visiting US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Cariprazine Breastfeeding Warnings

Safety has not been established. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc., Parsippany, NJ.

References for breastfeeding information

  1. "Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc., Parsippany, NJ.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.